The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients

Objectives: To verify the effectiveness of G-CSF in the treatment of non-healing skin lesions in SSc patients. Methods: 26 SSc patients (23 F and 3 M, age 54 ±13,6 yrs) with skin ulcers were enrolled in a pilot study. Prior to the treatment with G-CSF, all ulcers failed to heal with conventional the...

Full description

Bibliographic Details
Main Authors: Andrea Caruso, Umberto Franciosi, Michele Colaci, Rocco Magistro, Dilia Giuggioli, Clodoveo Ferri
Format: Article
Language:English
Published: PAGEPress Publications 2011-09-01
Series:Reumatismo
Online Access:http://www.reumatismo.org/index.php/reuma/article/view/246
id doaj-dccbddbf6d8c4c62bc304af39b73c955
record_format Article
spelling doaj-dccbddbf6d8c4c62bc304af39b73c9552020-11-24T21:06:04ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-01581263010.4081/reumatismo.2006.26The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patientsAndrea CarusoUmberto FranciosiMichele ColaciRocco MagistroDilia GiuggioliClodoveo FerriObjectives: To verify the effectiveness of G-CSF in the treatment of non-healing skin lesions in SSc patients. Methods: 26 SSc patients (23 F and 3 M, age 54 ±13,6 yrs) with skin ulcers were enrolled in a pilot study. Prior to the treatment with G-CSF, all ulcers failed to heal with conventional therapies carried out for a period of 1-5 years. All patients were treated with 5μg/kg G-CSF subcutaneously for 5 days. Healing time, quality of wounds, VAS and HAQ-DI were used to evaluate the efficacy of the treatment. Results: An improvement of skin ulcers was observed in 24/26 patients; in particular, 22/26 wounds completely healed, 2/26 showed a partial healing, in only 2 patients skin ulcers did not change during the 6-month follow-up. The quality of life improves as showed by VAS (from 88±13 to 55±28; p<.0001) and HAQ (from 2.12 ±0.45 to 1.28±0.30; p<.0001). The eradication of pathogens from the infected ulcers was also observed in 12/12 patients; while no adverse side effects related to G-CSF were recorded. Our study suggests that G-CSF may be usefully employed in scleroderma skin ulcers refractory to conventional treatments.http://www.reumatismo.org/index.php/reuma/article/view/246
collection DOAJ
language English
format Article
sources DOAJ
author Andrea Caruso
Umberto Franciosi
Michele Colaci
Rocco Magistro
Dilia Giuggioli
Clodoveo Ferri
spellingShingle Andrea Caruso
Umberto Franciosi
Michele Colaci
Rocco Magistro
Dilia Giuggioli
Clodoveo Ferri
The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients
Reumatismo
author_facet Andrea Caruso
Umberto Franciosi
Michele Colaci
Rocco Magistro
Dilia Giuggioli
Clodoveo Ferri
author_sort Andrea Caruso
title The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients
title_short The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients
title_full The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients
title_fullStr The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients
title_full_unstemmed The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients
title_sort treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (g-csf) in 26 patients
publisher PAGEPress Publications
series Reumatismo
issn 0048-7449
2240-2683
publishDate 2011-09-01
description Objectives: To verify the effectiveness of G-CSF in the treatment of non-healing skin lesions in SSc patients. Methods: 26 SSc patients (23 F and 3 M, age 54 ±13,6 yrs) with skin ulcers were enrolled in a pilot study. Prior to the treatment with G-CSF, all ulcers failed to heal with conventional therapies carried out for a period of 1-5 years. All patients were treated with 5μg/kg G-CSF subcutaneously for 5 days. Healing time, quality of wounds, VAS and HAQ-DI were used to evaluate the efficacy of the treatment. Results: An improvement of skin ulcers was observed in 24/26 patients; in particular, 22/26 wounds completely healed, 2/26 showed a partial healing, in only 2 patients skin ulcers did not change during the 6-month follow-up. The quality of life improves as showed by VAS (from 88±13 to 55±28; p<.0001) and HAQ (from 2.12 ±0.45 to 1.28±0.30; p<.0001). The eradication of pathogens from the infected ulcers was also observed in 12/12 patients; while no adverse side effects related to G-CSF were recorded. Our study suggests that G-CSF may be usefully employed in scleroderma skin ulcers refractory to conventional treatments.
url http://www.reumatismo.org/index.php/reuma/article/view/246
work_keys_str_mv AT andreacaruso thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT umbertofranciosi thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT michelecolaci thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT roccomagistro thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT diliagiuggioli thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT clodoveoferri thetreatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT andreacaruso treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT umbertofranciosi treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT michelecolaci treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT roccomagistro treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT diliagiuggioli treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
AT clodoveoferri treatmentofskinulcersinsystemicsclerosisuseofgranulocytecolonystimulatingfactorgcsfin26patients
_version_ 1716766882999042048